Mass. Movers

ImmunoGen climbs on Novartis deal


Shares of Waltham’s ImmunoGen Inc., a biotech firm that develops novel anticancer therapeutics using its antibody-drug conjugate technology, rose on a license deal with Novartis to use the company’s ADC technology to develop anticancer therapeutics. ImmunoGen said the Swiss drug giant would pay an upfront fee plus milestone payments of up to $200 million, with royalties from any approved drugs on top of that. This is the second licensing deal Novartis has to use ImmunoGen’s technology.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of